21 Result(s)

Article

Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study

Severe asthma is associated with airway inflammation and airway obstruction. In the phase 3 NAVIGATOR study, tezepelumab treatment significantly improved pre-bronchodilator forced expiratory volume in 1 s (FEV₁) ...

Andrew Menzies-Gow, Christopher S. Ambrose, Gene Colice… in Advances in Therapy (2023)

Article

A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma

Asthma affects 339 million people worldwide, with an estimated 5–10% experiencing severe asthma. In emergency settings, oral corticosteroids (OCS) can be lifesaving, but acute and long-term treatment can produ...

John Haughney, Tonya Winders, Steve Holmes, Pascal Chanez… in Advances in Therapy (2023)

Article

Application of an algorithm to analyze patterns of intermittent oral corticosteroid use in asthma

An algorithm to describe patterns of intermittent oral corticosteroid use in the UK (n = 476,167) found that one-third of patients receiving intermittent oral corticosteroids for asthma only had short gaps (<90 d...

John Haughney, Trung N. Tran, Heath Heatley… in npj Primary Care Respiratory Medicine (2023)

Article

A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma

Asthma is a heterogenous respiratory disease, usually associated with chronic airway inflammation and hyper-responsiveness, which affects an estimated 339 million people worldwide. Severe asthma affects approx...

Andrew Menzies-Gow, David J. Jackson, Mona Al-Ahmad… in Advances in Therapy (2022)

Article

A Response to: Letter to the Editor Regarding “Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab”

Andrew Menzies-Gow, Flavia L. Hoyte, David B. Price, David Cohen… in Advances in Therapy (2022)

Article

Environmental Sustainability in Respiratory Care: An Overview of the healthCARe-Based envirONmental Cost of Treatment (CARBON) Programme

Faced with the challenges of climate change, countries are seeking to decarbonise their economies. A greater understanding of what comprises the carbon footprint of care in healthcare systems will identify pot...

Alex Wilkinson, Ekaterina Maslova, Christer Janson, Yang Xu… in Advances in Therapy (2022)

Article

Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

Consensus definitions for clinical remission and super-response were recently established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed monoclonal antibody for severe, uncontro...

Andrew Menzies-Gow, Flavia L. Hoyte, David B. Price, David Cohen… in Advances in Therapy (2022)

Article

DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma

Tezepelumab is a human monoclonal antibody that blocks the activity of the epithelial cytokine thymic stromal lymphopoietin. The efficacy, safety and oral corticosteroid-sparing potential of tezepelumab are be...

Andrew Menzies-Gow, Sandhia Ponnarambil, John Downie, Karin Bowen… in Respiratory Research (2020)

Article

Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?

Despite treatment with standard-of-care medications, including currently available biologic therapies, many patients with severe asthma have uncontrolled disease, which is associated with a high risk of hospit...

Andrew Menzies-Gow, Michael E. Wechsler, Chris E. Brightling in Respiratory Research (2020)

Article

NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma

Patients with severe, uncontrolled asthma have a significant unmet need for new treatments that have broader effects on airway inflammation, and that provide greater improvements in asthma outcomes than curren...

Andrew Menzies-Gow, Gene Colice, Janet M. Griffiths, Gun Almqvist… in Respiratory Research (2020)

Article

Validation of subscales of the Severe Asthma Questionnaire (SAQ) using exploratory factor analysis (EFA)

The Severe Asthma Questionnaire (SAQ) is a health related quality of life (HRQoL) questionnaire validated for use in severe asthma. It is scored using the mean value of 16 items (SAQ score) in addition to a si...

Joseph W. Lanario, Michael E. Hyland… in Health and Quality of Life Outcomes (2020)

Article

Global Quality Standard for Identification and Management of Severe Asthma

Severe asthma is a debilitating, life-threatening disease associated with substantial global morbidity, mortality, and health care resource utilization. Patients may not receive guideline-directed medical care...

John Haughney, Tonya A. Winders, Steve Holmes, Pascal Chanez… in Advances in Therapy (2020)

Article

International severe asthma registry (ISAR): protocol for a global registry

Severe asthma exerts a disproportionately heavy burden on patients and health care. Due to the heterogeneity of the severe asthma population, many patients need to be evaluated to understand the clinical featu...

J. Mark FitzGerald, Trung N. Tran, Marianna Alacqua… in BMC Medical Research Methodology (2020)

Article

SABINA: An Overview of Short-Acting β₂-Agonist Use in Asthma in European Countries

Globally, individuals with asthma tend to overrely on short-acting β₂-agonists (SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying inflammation. Such relief-seeking behavior has bee...

Christer Janson, Andrew Menzies-Gow, Cassandra Nan, Javier Nuevo… in Advances in Therapy (2020)

Article

A Charter to Improve Patient Care in Severe Asthma

Severe asthma is a subtype of asthma that is difficult to treat and control. By conservative estimates, severe asthma affects approximately 5–10% of patients with asthma worldwide. Severe asthma impairs patien...

Andrew Menzies-Gow, G-Walter Canonica, Tonya A. Winders… in Advances in Therapy (2018)

Article

Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab

Previous studies showed that mepolizumab significantly reduces exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma. However, early studies reported inconsistent effects on lun...

Hector Ortega, Andrew Menzies-Gow, Jean-Pierre Llanos, Mark Forshag… in Advances in Therapy (2018)

Article

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial

Patients with difficult-to-control asthma consume 50–60% of healthcare costs attributed to asthma and cost approximately five-times more than patients with mild stable disease. Recent evidence demonstrates tha...

Catherine E. Hanratty, John G. Matthews, Joseph R. Arron, David F. Choy… in Trials (2018)

Article

Perceptions of asthma control in the United Kingdom: a cross-sectional study comparing patient and healthcare professionals’ perceptions of asthma control with validated ACT scores

Perceptions of asthma control often vary between patients and physicians. This cross-sectional survey provided UK-specific data on actual and perceived asthma control in patients (18–75 years) attending routin...

Andrew Menzies-Gow, Gavin Chiu in npj Primary Care Respiratory Medicine (2017)

Article

Severe Asthma: Challenges and Precision Approaches to Therapy

Current therapies are inadequate for patients with severe asthma. The development of biomarkers and novel targeted therapies should allow for the introduction of precision medicine for patients with severe ast...

Kjell Larsson, Andrew Menzies-Gow, Reynold A. Panettieri Jr in Pulmonary Therapy (2016)

Article

Sputum and serum hydrogen sulfide (H₂S) as novel biomarker of asthma

Junpei Saito, Pankaj Bhavsar, Qingling Zhang… in Clinical and Translational Allergy (2013)